Table 1.
Case-control studies of PKLR rs3020781 and NOS1AP rs7538490 in relation to type 2 diabetes, overweight and obesity
| PKLR rs3020781 | |||||||
|
n (men/women) |
TT (%) |
TC (%) |
CC (%) |
MAF (95% CI) |
pAF |
OR (95% CI) |
|
| NGT | 4,736 (2,209/2,527) |
2,602 (55) | 1,812 (38) | 322 (7) |
25.9 (25.0–26.8) |
0.49 | 1.02 (0.96–1.10) |
| T2D | 3,674 (2,187/1,487) |
1,998 (54) | 1,412 (39) | 264 (7) |
26.4 (25.4–27.4) |
||
| BMI < 25 (kg/m2) | 5,036 (2,111/2,925) |
2,732 (54) |
1,952 (39) |
352 (7) |
26.4 (25.5–27.2) |
||
| 25 ≤ BMI < 30 (kg/m2) | 6,985 (4,359/2,626) |
3,821 (55) |
2,700 (39) |
464 (6) |
26.0 (25.2–26.7) |
0.49 | 0.98 (0.92–1.04) |
| BMI ≤ 30 (kg/m2) | 4,780 (2,467/2,313) |
2,612 (55) |
1,845 (38) |
323 (7) |
26.2 (25.3–27.1) |
0.81 | 0.99 (0.93–1.06) |
| NOS1AP rs7538490 | |||||||
| n (men/women) |
CC (%) |
CT (%) |
TT (%) |
MAF (95% CI) |
pAF |
OR (95% CI) |
|
| NGT | 4,755 (2,218/2,537) |
2,479 (52) | 1,914 (40) | 362 (8) |
27.7 (26.8–28.7) |
0.84 | 0.99 (0.93–1.06) |
| T2D | 3,692 (2,200/1,492) |
1,954 (53) | 1,439 (39) | 299 (8) |
27.6 (26.6–28.6) |
||
| BMI < 25 (kg/m2) | 5,064 (2,128/2,936) |
2,635 (52) |
2,013 (40) |
416 (8) |
28.1 (27.2–29.0) |
||
| 25 ≤ BMI < 30 (kg/m2) | 7,030 (4,384/2,646) | 3,628 (51) |
2,857 (41) |
545 (8) |
28.1 (27.3–28.8) |
0.48 | 0.95 (0.83–1.09) |
| BMI ≥ 30 (kg/m2) | 4,819 (2,490/2,329) |
2,517 (52) |
1,923 (40) |
379 (8) |
27.8 (26.9–28.7) |
0.68 | 0.99 (0.93–1.05) |
Data are number of individuals, divided into genotype groups (% in each group), and frequencies of the minor allele (MAF) in percentages. Fisher's exact test was used to compare allele frequencies (pAF). The odds ratios (OR) and 95% confidence interval (CI) are given for comparison of allele frequency. NGT: individuals with normal glucose tolerance, T2D: type 2 diabetic patients.